This implies that passive immunization with tau antibodies is a feasible therapeutic target and that the CSF level of p-tau262/356 or of your microtubule binding domain (MTBD) can function a practical biomarker of tau pathology to monitor tau therapeutics in clinical trials.Regardless of these promising improvements, you will discover problems to h… Read More